What the FDA labels say about taking them together
Medroxyprogesterone and ospemifene
Ospemifene's FDA label of February 14, 2025 names medroxyprogesterone in its warnings and precautions section; the medroxyprogesterone labels PlainMeds reads (3) do not name ospemifene. The ospemifene label: “After a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus medroxyprogesterone acetate (MPA) (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA …”
Check it at the source: the medroxyprogesterone FDA label on DailyMed (effective June 29, 2026, Pharmacia & Upjohn Company LLC); the ospemifene FDA label on DailyMed (effective February 14, 2025, Duchesnay USA, Inc.).
What does the medroxyprogesterone label say about ospemifene?
Medroxyprogesterone's label (effective June 29, 2026) and its 2 other brand-application labels do not name ospemifene in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Provera), NDA011839 (Pfizer), as published by Pharmacia & Upjohn Company LLC, effective June 29, 2026 (SPL set a586be28-96af-4fed-a13f-9b94fd4c7405), via openFDA; the full label on DailyMed
What does the ospemifene label say about medroxyprogesterone?
Ospemifene label, warnings and precautionsAfter a mean follow-up of 5.6 years, the WHI substudy of daily CE (0.625 mg) plus medroxyprogesterone acetate (MPA) (2.5 mg) reported an increased risk of invasive breast cancer in women who took daily CE plus MPA compared to placebo.
Source: FDA drug label (Osphena), Duchesnay USA, Inc., effective February 14, 2025 (SPL set 9accbcc9-78ee-4f84-9b7e-704f2ab1c413), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Medroxyprogesterone | Ospemifene | |
|---|---|---|
| Labeled for | Birth control, Pain | Menopause symptoms |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $22.85 per mL 150 mg/mL | $8.17 per tablet 60 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once